News
Approval based on NIAGARA Phase III trial results which showed a 32% reduction in the risk of recurrence and a 25% reduction in the risk of death for the ...
CINCINNATI, OH, USA I July 4, 2025 I During the COVID-19 pandemic, scientists learned that the critical path to infection started with the SARS-CoV-2 virus ...
BOSTON, MA, USA I July 4, 2025 I HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, small molecule ...
GUANGZHOU, China I July 2, 2025 I Bio-Thera Solutions, Inc. (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, today announced ...
BOSTON, MA, USA I July 02, 2025 I Modella AI, a leader in artificial intelligence for life sciences, today announced a multi-year agreement with AstraZeneca. Under the agreement, Modella AI will ...
MONTREAL, Canada I July 02, 2025 I Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage ...
DURHAM, NC, USA and BEIJING, China I July 3, 2025 I Brii Biosciences Limited ("Brii Bio," stock code: 2137.HK), a biotechnology company developing ...
BEIJING, China I July 03, 2025 I InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and ...
EMERYVILLE, CA, USA I July 02, 2025 I 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing ...
EAST HANOVER, NJ, USA I July 3, 2025 I Novartis today announced top-line results from the Phase III GCAptAIN study evaluating Cosentyx® (secukinumab) in ...
RAHWAY, NJ, USA I July 02, 2025 I Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results